Company Overview of Second Genome, Inc.
Second Genome, Inc., a biopharmaceutical company, focuses on the microbiome drug discovery and development. Its lead candidate SGM-1019 is a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in inflammatory bowel disease (IBD). The company is also involved in various preclinical programs under development for a range of chronic indications. Second Genome, Inc. has strategic partnerships with Janssen Biotech and Mayo Clinic. It was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in South San Francisco, California.
341 Allerton Avenue
South San Francisco, CA 94080
Founded in 2009
Key Executives for Second Genome, Inc.
Second Genome, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
April 20, 2016
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Second Genome, Inc., please visit www.secondgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.